Have a personal or library account? Click to login
RANKL is a new epigenetic biomarker for the vasomotor symptom during Menopause Cover

RANKL is a new epigenetic biomarker for the vasomotor symptom during Menopause

By: R Kalkan,  M Altarda and  O Tosun  
Open Access
|Aug 2020

Figures & Tables

Figure 1

Methylated RANKL patient. The RANKL unmethylated control is purple, methylated control is red. Patient #50 was methylated and patient #52 was unmethylated.
Methylated RANKL patient. The RANKL unmethylated control is purple, methylated control is red. Patient #50 was methylated and patient #52 was unmethylated.

Methylation status of RANKL and FSHR genes in pre- and postmenopausal women_

GenesPostmenopausePremenopausePositive Hot Flashes HistoryNegative Hot Flashes History
RANKL (M) n16 (45.7%)10 (33.3%)12 (75.0%)4 (25.0%)
RANKL (U) n19 (54.3%)20 (66.7%)7 (36.8%)12 (63.2%)
FSHR(M) n18 (51.4%)20 (66.7%)13 (72.2%)5 (27.8%)
FSHR (U) n17 (48.6%)10 (33.3%)6 (35.3%)11 (64.7%)

Methylation status of RANKL and FSHR genes and postmenopausal women who have hot flashes_

GenesPositive Hot Flashes HistoryNegative Hot Flashes Historyp Value
RANKL (M) n12 (75.0%)4 (25.0%)0.024
RANKL (U) n7 (36.8%)12 (63.2%)
FSHR(M) n13 (72.2%)5 (27.8%)0.028
FSHR (U) n6 (35.3%)11 (64.7%)
Language: English
Page range: 51 - 56
Published on: Aug 26, 2020
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2020 R Kalkan, M Altarda, O Tosun, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.